Currently out of the existing stock ratings of Mohit Bansal, 193 are a BUY (63.91%), 107 are a HOLD (35.43%), 2 are a SELL (0.66%).

Mohit Bansal

Work Performance Price Targets & Ratings Chart

Analyst Mohit Bansal, currently employed at WELLS FARGO, carries an average stock price target met ratio of 63.04% that have a potential upside of 29.92% achieved within 236 days. Previously, Mohit Bansal worked at DEUTSCHE BANK, CITI.

Mohit Bansal’s has documented 587 price targets and ratings displayed on 40 stocks. The coverage is on Healthcare, Consumer Cyclical sectors.

Most recent stock forecast was given on TVTX, Travere Therapeutics at 12-Jun-2026.

Wall Street Analyst Mohit Bansal

Analyst best performing recommendations are on RDUS (SCHNITZER STEEL INDUSTRIES).
The best stock recommendation documented was for VRTX (VERTEX PHARMACEUTICALS) at 1/30/2025. The price target of $460 was fulfilled within 1 day with a profit of $21.6 (4.93%) receiving and performance score of 49.27.

Average potential price target upside

of $91.03 (14.52%) on LLY (ELI LILLY AND COMPANY).
of $56.14 (20.87%) on VRTX (VERTEX PHARMACEUTICALS).
of $42.6 (29.46%) on ABBV (ABBVIE).

AGIO Agios Pharm ALXN Alexion Pharmaceuticals AMGN Amgen BIIB Biogen BMRN Biomarin Pharmaceutical CALA Calithera Biosciences CHRS Coherus BioSciences CTMX CytomX Therapeutics EPZM Epizyme FOLD Amicus Therapeutics GILD Gilead Sciences LLY Eli Lilly and Company MYOK MyoKardia MYOV Myovant Sciences Ltd PFE Pfizer RDUS Schnitzer Steel Industries REGN Regeneron Pharmaceuticals VRTX Vertex Pharmaceuticals ABBV AbbVie BMY Bristol-Myers Squibb Company KRTX Karuna Therapeutics MRK Merck mpany SNSE Sensei Biotherapeutics STTK Shattuck Labs NBIX Neurocrine Biosciences BOLD Audentes Therapeutics CERE Cerevel Therapeutics Holdings HALO Halozyme Therapeutics ONCE Spark Therapeutics KDNY Chinook Therapeutics IRWD Ironwood Pharmaceuticals TVTX Travere Therapeutics JAZZ Jazz Pharmaceuticals PLC XENE Xenon Pharmaceuticals BNTX BioNTech SE FBRX Forte Biosciences IDYA Ideaya Biosciences MIST Milestone Pharmaceuticals CAL Caleres MLYS Mineralys Therapeutics, Common Stock

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Tessa Romero (JPMORGAN)